ARK Genomic Revolution ETF (ARKG)

BATS: ARKG · IEX Real-Time Price · USD
32.96
+1.54 (4.90%)
Feb 27, 2024, 4:00 PM EST - Market closed
4.90%
Assets $1.91B
Expense Ratio 0.75%
PE Ratio n/a
Shares Out 59.70M
Dividend (ttm) n/a
Dividend Yield n/a
Ex-Dividend Date n/a
Payout Ratio n/a
1-Year Return +10.12%
Volume 3,031,710
Open 32.06
Previous Close 31.42
Day's Range 31.73 - 33.15
52-Week Low 21.97
52-Week High 38.97
Beta 1.97
Holdings 42
Inception Date Oct 31, 2014

About ARKG

Fund Home Page

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is issued by ARK.

Asset Class Equity
Category Health
Stock Exchange BATS
Ticker Symbol ARKG
ETF Provider ARK

Top 10 Holdings

51.15% of assets
Name Symbol Weight
CRISPR Therapeutics AG CRSP 8.43%
Recursion Pharmaceuticals, Inc. RXRX 7.11%
Twist Bioscience Corporation TWST 6.16%
Exact Sciences Corporation EXAS 5.35%
Schrödinger, Inc. SDGR 4.48%
Beam Therapeutics Inc. BEAM 4.34%
Ginkgo Bioworks Holdings, Inc. DNA 4.05%
Arcturus Therapeutics Holdings Inc. ARCT 3.91%
10x Genomics, Inc. TXG 3.68%
Ionis Pharmaceuticals, Inc. IONS 3.64%
View More Holdings

Dividends

Ex-Dividend Amount Pay Date
Dec 29, 2021 $0.38239 Dec 31, 2021
Dec 29, 2020 $0.79013 Dec 31, 2020
Dec 27, 2019 $1.05395 Dec 31, 2019
Dec 27, 2018 $0.466 Dec 31, 2018
Dec 27, 2017 $0.328 Dec 29, 2017
Full Dividend History

News

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Hi! This week's ETF Wrap funds looks at China-focused funds that are struggling in 2024, with Clocktower's chief strategist Marko Papic providing his take on concerns tied to the country.

5 weeks ago - Market Watch

Best Healthcare ETFs to Buy Now

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

Other symbols: FXHIXJVHTXBIXLV
2 months ago - Kiplinger

VIDEO: ETF of the Week: ARK Genomic Revolution ETF (ARKG)

On this episode of the “ETF of the Week” podcast, Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) with Chuck Jaffe of “Money Life.” The pair talked about several topics regarding the fund to...

2 months ago - ETF Trends

ETF of the Week: ARK Genomic Revolution ETF (ARKG)

VettaFi's vice chairman Tom Lydon discussed the ARK Genomic Revolution ETF (ARKG) on this week's “ETF of the Week” podcast with Chuck Jaffe of “Money Life.” For more news, information, and analysis, v...

2 months ago - ETF Trends

VettaFi Voices On: The Outlook for 2024

Good morning, VettaFi Voices! We are a week out from the VettaFi 2024 Market Outlook Symposium on December 14, which will feature a range of ETF industry leaders discussing their expectations for diff...

2 months ago - ETF Trends

VettaFi Voices On: Accessing Disruptive Innovation

Good Morning, VettaFi Voices! Disruptive innovation is a popular topic, and it encompasses everything from bitcoin and cryptocurrency to electric vehicles to artificial intelligence.

3 months ago - ETF Trends

ETF Prime: Crigger on ARK Invest's Future and More 

On this episode of ETF Prime, host Nate Geraci speaks with a pair of individuals discussing several different ETF-related topics. His guests include VettaFi's Lara Crigger, who discusses ARK Invest's ...

Other symbols: ARKKARKQ
4 months ago - ETF Trends

How to Find the Best Biotech ETFs

The best biotech ETFs allow investors a diversified way to play the volatile biotechnology industry. Here's how to find them.

Other symbols: IBBXBI
4 months ago - Kiplinger

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

ARK Invest CEO and CIO Cathie Wood comments on ARK's fund flows during an interview with Romaine Bostick and Katie Greifeld on "Bloomberg Markets: The Close."

Other symbols: ARKFARKKARKW
8 months ago - Bloomberg Markets and Finance

ARKG: Smart Idea for Smart Advancements in Cancer Treatment

The cancer treatment/immuno-oncology market is expansive and ripe with potential for long-term healthcare investors. Predictably, there are significant implications for biotechnology and genomics comp...

11 months ago - ETF Trends

Biotech ETFs' Performance Deserves A Look

Biotech comes with a great many positive externalities for society, and can be a big positive for portfolios right now.

Other symbols: SBIOXBI
11 months ago - ETF Trends

Genomics Outlook for Disruption Is Rising

Biotechnology and genomics equities are showing modest signs of life this year following dismal showings in 2022. The good news for long-term investors is that there could well be much more to come, p...

11 months ago - ETF Trends

Thematic Index Lineup Joins VettaFi and the Future Is Bright

A decade ago, when the ROBO Global Robotics & Automation Index ETF (ROBO) launched, the U.S. thematic ETF market was nascent, with only a handful of products and minimal assets. However, at the end of...

11 months ago - ETF Trends

This Stock Could Propel Genomics ETFs

Under most circumstances, stock picking is difficult, and that difficulty level is ratcheted higher in the disruptive technology space. That's certainly true of genomics investing where fortunes are b...

11 months ago - ETF Trends

Innovation Is Crucial to Healthcare Sector Long-Term Growth

Experienced healthcare investors know several important facts regarding large-cap, blue-chip biopharma companies. First, these firms enjoy a limited amount of time when their blockbuster drugs corner ...

1 year ago - ETF Trends

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

Cathie Wood of ARK Invest joins 'Squawk on the Street' to discuss her thoughts on the tech space, banking crisis and more.

Other symbols: ARKKARKW
1 year ago - CNBC Television

Outlook for Healthcare Innovation Is Brightening

Healthcare is an epicenter of innovation, and some exchange traded funds put investors front and center when it comes to accessing that theme. Count the ARK Genomic Revolution ETF (ARKG) as one of the...

1 year ago - ETF Trends

These Segments Could Power ARK Genomics ETF

Genomics is one of the epicenters of healthcare innovation and that will remain true for years to come. For investors looking to tap into that theme, it pays to examine some of the catalysts that will...

1 year ago - ETF Trends

Bright Future for this Disruptive Healthcare ETF

The healthcare sector has long been a mecca of innovation and one of the key elements in that theme is the evolution of genetics. Not only does that profound effects on patient outcomes, but there are...

1 year ago - ETF Trends

Eye DNA Synthesis Advances in Active Biotech ETF ARKG

It's hard to imagine it now, but at the turn of the millennium, the big advancement in technology was not the latest phone app, it was the Human Genome Project. Since then, genetics advancements are n...

1 year ago - ETF Trends

Get Benefits From Innovator ACCD in Health Tech ETF ARKG

For all the concerns surrounding tech investments over the last year, with mega-cap tech names like Amazon (AMZN) and Meta (META) being the poster children for the broad market selloff, biotech remain...

1 year ago - ETF Trends

EXAS Nears Key Buy Signal in Active Biotech ETF ARKG

There are a lot of reasons to be skeptical of tech investing right now since last year's broad market selloff — just how far is the Fed planning to go with rising rates this year, anyway? Still, there...

1 year ago - ETF Trends

Why Now Could Be Time to Buy No Cap Gain ARK Strats

Ready for the new year? It wouldn't be surprising for most ETF investors to be excited to put 2022 in the rear view.

Other symbols: ARKK
1 year ago - ETF Trends

Top-Read Disruptive Technology Stories of 2022

2022 has been a wild year for markets, from Russia's invasion of Ukraine to the Fed's dedicated rate hike campaign. That hasn't stopped the world from innovating, though, with firms in areas from biot...

Other symbols: ARKK
1 year ago - ETF Trends

ARK Continues Contrarian Plays in ETFs TSLA, COIN, VERV

ARK Invest and CEO Cathie Wood have once again bought the dip on firms the company believes have long term potential to be real innovators, adding shares from Tesla (TSLA), Coinbase (COIN), and Verve ...

Other symbols: ARKQARKW
1 year ago - ETF Trends